#METABOLOMICS WORKBENCH xliu68_20251211_153833 DATATRACK_ID:6875 STUDY_ID:ST004439 ANALYSIS_ID:AN007434 PROJECT_ID:PR002803 VERSION 1 CREATED_ON December 11, 2025, 4:32 pm #PROJECT PR:PROJECT_TITLE NAPRT-mediated deamidated NAD biosynthesis enhances tissue resiliency and PR:PROJECT_TITLE suppresses tumorigenesis PR:PROJECT_SUMMARY Nicotinamide adenine dinucleotide (NAD) biosynthetic enzymes are currently PR:PROJECT_SUMMARY believed to be oncogenic, as they are frequently overexpressed in cancer to PR:PROJECT_SUMMARY maintain an increased metabolic demand. Here we report a tumor suppressing role PR:PROJECT_SUMMARY of the deamidated arm of NAD biosynthesis in both mice and humans. In contrast PR:PROJECT_SUMMARY to the ubiquitous expression of the key enzyme in the amidated NAD salvage PR:PROJECT_SUMMARY pathway, nicotinic acid phosphoribosyl transferase (NAPRT), the first enzyme of PR:PROJECT_SUMMARY the deamidated pathway, is specifically enriched in gut epithelial cells, where PR:PROJECT_SUMMARY it maintains the NAD pool for an efficient response to stress-induced acute NAD PR:PROJECT_SUMMARY depletion. Consequently, NAPRT deficiency impairs the activity of PR:PROJECT_SUMMARY poly-(ADP-ribose) polymerases and DNA repair, sensitizes mice to PR:PROJECT_SUMMARY chemical-induced colitis and tumorigenesis as well as to age-associated PR:PROJECT_SUMMARY spontaneous tumor development. In several human cancer types, low NAPRT PR:PROJECT_SUMMARY expression is associated with poor prognosis. Therefore, endogenous deamidated PR:PROJECT_SUMMARY NAD biosynthesis suppresses tumorigenesis, and its boosting may be beneficial PR:PROJECT_SUMMARY for tumor prevention. PR:INSTITUTE North Carolina State University PR:LAST_NAME Liu PR:FIRST_NAME Xiaojing PR:ADDRESS Department of Molecular and Structural Biochemistry, North Carolina State PR:ADDRESS University, Raleigh, North Carolina 27695, United States PR:EMAIL xliu68@ncsu.edu PR:PHONE 919-515-4387 #STUDY ST:STUDY_TITLE Quantitative LC-MS analysis of NAR in mouse plasma ST:STUDY_SUMMARY Mouse plasma (5 µL) was extracted using 13C-yeast internal standard and ST:STUDY_SUMMARY methanol, then centrifuged, and the supernatant was analyzed by UHPLC–MS. ST:STUDY_SUMMARY Metabolites were separated on a BEH Amide column using an acetonitrile–water ST:STUDY_SUMMARY gradient, and detected on an Exploris 480 mass spectrometer with standardized ST:STUDY_SUMMARY ionization settings. Calibration standards spiked into 13C-yeast extract were ST:STUDY_SUMMARY used to determine internal-standard concentration and ion-response factors. For ST:STUDY_SUMMARY nicotinic acid riboside (NAR) analysis, due to interference in the D4-NAR (M+4) ST:STUDY_SUMMARY channel at MS1 level, characteristic fragment ions (m/z 124.0392, 127.0581, ST:STUDY_SUMMARY 128.0643, and 130.0594) from MS2 spectra of NAR, D3-NAR, D4-NAR, and 13 C-NAR ST:STUDY_SUMMARY precursors were used for quantification. MS2 data acquisition was performed with ST:STUDY_SUMMARY the following parameters: isolation window, 0.8 m/z; HCD collision energy, 30%; ST:STUDY_SUMMARY resolution, 30,000; and a targeted mass list of m/z 256.0816, 259.1004, ST:STUDY_SUMMARY 260.1067, and 267.1185. To determine the concentration of 13 C-labeled NAR in ST:STUDY_SUMMARY the yeast extract, standards of NAR (0.16 and 0.8 ng/µL) were spiked into 5 µL ST:STUDY_SUMMARY 13 C yeast extract, followed by methanol extraction and LC–MS analysis. ST:STUDY_SUMMARY Skyline was used for MS2-based quantification, ST:INSTITUTE North Carolina State University ST:LAST_NAME Liu ST:FIRST_NAME Xiaojing ST:ADDRESS Department of Molecular and Structural Biochemistry, North Carolina State ST:ADDRESS University, Raleigh, North Carolina 27695, United States ST:EMAIL xliu68@ncsu.edu ST:PHONE 919-515-4387 #SUBJECT SU:SUBJECT_TYPE Mammal SU:SUBJECT_SPECIES Mus musculus SU:TAXONOMY_ID 10090 #SUBJECT_SAMPLE_FACTORS: SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Raw file names and additional sample data SUBJECT_SAMPLE_FACTORS 818 818 Genotype:WT | Treatment:PBS | Treatment duration (hr):0 | Sample source:plasma Sample type=Sample; RAW_FILE_NAME(Raw file name)=818.mzML SUBJECT_SAMPLE_FACTORS 819 819 Genotype:WT | Treatment:PBS | Treatment duration (hr):0 | Sample source:plasma Sample type=Sample; RAW_FILE_NAME(Raw file name)=819.mzML SUBJECT_SAMPLE_FACTORS 830 830 Genotype:KO | Treatment:PBS | Treatment duration (hr):0 | Sample source:plasma Sample type=Sample; RAW_FILE_NAME(Raw file name)=830.mzML SUBJECT_SAMPLE_FACTORS 831 831 Genotype:KO | Treatment:PBS | Treatment duration (hr):0 | Sample source:plasma Sample type=Sample; RAW_FILE_NAME(Raw file name)=831.mzML SUBJECT_SAMPLE_FACTORS 895 895 Genotype:KO | Treatment:PBS | Treatment duration (hr):0 | Sample source:plasma Sample type=Sample; RAW_FILE_NAME(Raw file name)=895.mzML SUBJECT_SAMPLE_FACTORS 908 908 Genotype:WT | Treatment:PBS | Treatment duration (hr):0 | Sample source:plasma Sample type=Sample; RAW_FILE_NAME(Raw file name)=908.mzML SUBJECT_SAMPLE_FACTORS 820 820 Genotype:WT | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):1 | Sample source:plasma Sample type=Sample; RAW_FILE_NAME(Raw file name)=820.mzML SUBJECT_SAMPLE_FACTORS 821 821 Genotype:WT | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):1 | Sample source:plasma Sample type=Sample; RAW_FILE_NAME(Raw file name)=821.mzML SUBJECT_SAMPLE_FACTORS 832 832 Genotype:KO | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):1 | Sample source:plasma Sample type=Sample; RAW_FILE_NAME(Raw file name)=832.mzML SUBJECT_SAMPLE_FACTORS 833 833 Genotype:KO | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):1 | Sample source:plasma Sample type=Sample; RAW_FILE_NAME(Raw file name)=833.mzML SUBJECT_SAMPLE_FACTORS 861 861 Genotype:KO | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):1 | Sample source:plasma Sample type=Sample; RAW_FILE_NAME(Raw file name)=861.mzML SUBJECT_SAMPLE_FACTORS 862 862 Genotype:KO | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):1 | Sample source:plasma Sample type=Sample; RAW_FILE_NAME(Raw file name)=862.mzML SUBJECT_SAMPLE_FACTORS 906 906 Genotype:WT | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):1 | Sample source:plasma Sample type=Sample; RAW_FILE_NAME(Raw file name)=906.mzML SUBJECT_SAMPLE_FACTORS 907 907 Genotype:WT | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):1 | Sample source:plasma Sample type=Sample; RAW_FILE_NAME(Raw file name)=907.mzML SUBJECT_SAMPLE_FACTORS 824 824 Genotype:WT | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):3 | Sample source:plasma Sample type=Sample; RAW_FILE_NAME(Raw file name)=824.mzML SUBJECT_SAMPLE_FACTORS 825 825 Genotype:WT | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):3 | Sample source:plasma Sample type=Sample; RAW_FILE_NAME(Raw file name)=825.mzML SUBJECT_SAMPLE_FACTORS 834 834 Genotype:KO | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):3 | Sample source:plasma Sample type=Sample; RAW_FILE_NAME(Raw file name)=834.mzML SUBJECT_SAMPLE_FACTORS 840 840 Genotype:KO | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):3 | Sample source:plasma Sample type=Sample; RAW_FILE_NAME(Raw file name)=840.mzML SUBJECT_SAMPLE_FACTORS 846 846 Genotype:WT | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):3 | Sample source:plasma Sample type=Sample; RAW_FILE_NAME(Raw file name)=846.mzML SUBJECT_SAMPLE_FACTORS 847 847 Genotype:WT | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):3 | Sample source:plasma Sample type=Sample; RAW_FILE_NAME(Raw file name)=847.mzML SUBJECT_SAMPLE_FACTORS 852 852 Genotype:KO | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):3 | Sample source:plasma Sample type=Sample; RAW_FILE_NAME(Raw file name)=852.mzML SUBJECT_SAMPLE_FACTORS 853 853 Genotype:KO | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):3 | Sample source:plasma Sample type=Sample; RAW_FILE_NAME(Raw file name)=853.mzML SUBJECT_SAMPLE_FACTORS 826 826 Genotype:WT | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):6 | Sample source:plasma Sample type=Sample; RAW_FILE_NAME(Raw file name)=826.mzML SUBJECT_SAMPLE_FACTORS 827 827 Genotype:WT | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):6 | Sample source:plasma Sample type=Sample; RAW_FILE_NAME(Raw file name)=827.mzML SUBJECT_SAMPLE_FACTORS 842 842 Genotype:KO | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):6 | Sample source:plasma Sample type=Sample; RAW_FILE_NAME(Raw file name)=842.mzML SUBJECT_SAMPLE_FACTORS 844 844 Genotype:WT | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):6 | Sample source:plasma Sample type=Sample; RAW_FILE_NAME(Raw file name)=844.mzML SUBJECT_SAMPLE_FACTORS 845 845 Genotype:WT | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):6 | Sample source:plasma Sample type=Sample; RAW_FILE_NAME(Raw file name)=845.mzML SUBJECT_SAMPLE_FACTORS 837 837 Genotype:KO | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):6 | Sample source:plasma Sample type=Sample; RAW_FILE_NAME(Raw file name)=837.mzML SUBJECT_SAMPLE_FACTORS 836 836 Genotype:KO | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):6 | Sample source:plasma Sample type=Sample; RAW_FILE_NAME(Raw file name)=836.mzML SUBJECT_SAMPLE_FACTORS 880 880 Genotype:KO | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):6 | Sample source:plasma Sample type=Sample; RAW_FILE_NAME(Raw file name)=880.mzML SUBJECT_SAMPLE_FACTORS 881 881 Genotype:KO | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):6 | Sample source:plasma Sample type=Sample; RAW_FILE_NAME(Raw file name)=881.mzML SUBJECT_SAMPLE_FACTORS 835 835 Genotype:KO | Treatment:D4-NA 400 mg/kg | Treatment duration (hr):3 | Sample source:plasma Sample type=Sample; RAW_FILE_NAME(Raw file name)=835.mzML SUBJECT_SAMPLE_FACTORS 887 887 Genotype:WT | Treatment:D4-NA 400 mg/kg | Treatment duration (hr):3 | Sample source:plasma Sample type=Sample; RAW_FILE_NAME(Raw file name)=887.mzML SUBJECT_SAMPLE_FACTORS 888 888 Genotype:WT | Treatment:D4-NA 400 mg/kg | Treatment duration (hr):3 | Sample source:plasma Sample type=Sample; RAW_FILE_NAME(Raw file name)=888.mzML SUBJECT_SAMPLE_FACTORS 868 868 Genotype:KO | Treatment:D4-NA 400 mg/kg | Treatment duration (hr):3 | Sample source:plasma Sample type=Sample; RAW_FILE_NAME(Raw file name)=868.mzML SUBJECT_SAMPLE_FACTORS 869 869 Genotype:KO | Treatment:D4-NA 400 mg/kg | Treatment duration (hr):3 | Sample source:plasma Sample type=Sample; RAW_FILE_NAME(Raw file name)=869.mzML SUBJECT_SAMPLE_FACTORS 891 891 Genotype:WT | Treatment:D4-NA 400 mg/kg | Treatment duration (hr):3 | Sample source:plasma Sample type=Sample; RAW_FILE_NAME(Raw file name)=891.mzML SUBJECT_SAMPLE_FACTORS Std-YEmix2 Std-YEmix2 Genotype:- | Treatment:NAR standard and 13C yeast | Treatment duration (hr):- | Sample source:- Sample type=standard mixture; RAW_FILE_NAME(Raw file name)=Std-YEmix2.mzML SUBJECT_SAMPLE_FACTORS Std-YEmix3 Std-YEmix3 Genotype:- | Treatment:NAR standard and 13C yeast | Treatment duration (hr):- | Sample source:- Sample type=standard mixture; RAW_FILE_NAME(Raw file name)=Std-YEmix3.mzML #COLLECTION CO:COLLECTION_SUMMARY For D4-NAM isotopic tracing experiment, male WT and NAPRT KO mice, aged between CO:COLLECTION_SUMMARY eight to thirteen weeks, were orally administered either 80 mg/kg of CO:COLLECTION_SUMMARY nicotinamide labeled with four deuterium atoms on the pyridine ring (D4-NAM) or CO:COLLECTION_SUMMARY received a PBS gavage in the control group. To prevent any bias, gavages were CO:COLLECTION_SUMMARY staggered to keep the time between gavage and sacrifice constant and were CO:COLLECTION_SUMMARY administered alternately between the WT and NAPRT KO mice. The mice were CO:COLLECTION_SUMMARY euthanized at 0, 3, 6, or 24 hours after gavage administration, and small CO:COLLECTION_SUMMARY intestines and colons were flushed and flash-frozen in liquid nitrogen along CO:COLLECTION_SUMMARY with blood, liver, pancreas, kidneys, spleen, heart, lungs, quadriceps muscles, CO:COLLECTION_SUMMARY brain, white and brown adipose tissues. These samples were then preserved at -80 CO:COLLECTION_SUMMARY degrees until further processing. Each group receiving a specific treatment CO:COLLECTION_SUMMARY consisted of 4-5 mice. CO:SAMPLE_TYPE Blood (plasma) #TREATMENT TR:TREATMENT_SUMMARY For D4-NAM isotopic tracing experiment, male WT and NAPRT KO mice, aged between TR:TREATMENT_SUMMARY eight to thirteen weeks, were orally administered either 80 mg/kg of TR:TREATMENT_SUMMARY nicotinamide labeled with four deuterium atoms on the pyridine ring (D4-NAM) or TR:TREATMENT_SUMMARY received a PBS gavage in the control group. To prevent any bias, gavages were TR:TREATMENT_SUMMARY staggered to keep the time between gavage and sacrifice constant and were TR:TREATMENT_SUMMARY administered alternately between the WT and NAPRT KO mice. #SAMPLEPREP SP:SAMPLEPREP_SUMMARY 5 µL mouse plasma was mixed with 5 µL 13 C yeast extract, followed by the SP:SAMPLEPREP_SUMMARY addition of 40 µL ice-cold methanol. The mixture was vortexed for 1 min, kept SP:SAMPLEPREP_SUMMARY on ice for 10 min with occasional vortexing, and then centrifuged for 10 min at SP:SAMPLEPREP_SUMMARY 20,000 g at 4 °C. The supernatant was transferred to an LC vial, and 2 µL was SP:SAMPLEPREP_SUMMARY injected. For nicotinic acid riboside (NAR) analysis, due to interference in the SP:SAMPLEPREP_SUMMARY D4-NAR (M+4) channel at MS1 level, characteristic fragment ions (m/z 124.0392, SP:SAMPLEPREP_SUMMARY 127.0581, 128.0643, and 130.0594) from MS2 spectra of NAR, D3-NAR, D4-NAR, and SP:SAMPLEPREP_SUMMARY 13 C-NAR precursors were used for quantification. MS2 data acquisition was SP:SAMPLEPREP_SUMMARY performed with the following parameters: isolation window, 0.8 m/z; HCD SP:SAMPLEPREP_SUMMARY collision energy, 30%; resolution, 30,000; and a targeted mass list of m/z SP:SAMPLEPREP_SUMMARY 256.0816, 259.1004, 260.1067, and 267.1185. To determine the concentration of 13 SP:SAMPLEPREP_SUMMARY C-labeled NAR in the yeast extract, standards of NAR (0.16 and 0.8 ng/µL) were SP:SAMPLEPREP_SUMMARY spiked into 5 µL 13 C yeast extract, followed by methanol extraction and SP:SAMPLEPREP_SUMMARY LC–MS analysis. Skyline was used for MS2-based quantification. #CHROMATOGRAPHY CH:CHROMATOGRAPHY_SUMMARY polar (LC/MS Pos early) CH:CHROMATOGRAPHY_TYPE HILIC CH:INSTRUMENT_NAME Thermo Vanquish CH:COLUMN_NAME ACQUITY UPLC BEH Amide column (1 mm x 100 mm, 1.7 μm, Waters) CH:SOLVENT_A water with 5 mM ammonium acetate (pH 6.8) CH:SOLVENT_B 100% Acetonitrile CH:FLOW_GRADIENT The LC gradient was as follows: 0-1.5 min, 85% B; 5.5 min, 35% B; 10.5 min, 35% CH:FLOW_GRADIENT B; 10.6 min, 10% B; 12.5 min, 10% B; 13.5-20 min, 85% B. CH:FLOW_RATE 0.04 mL/min, except at 13.5 min when it was increased to 70 µL/min to CH:FLOW_RATE accelerate column re-equilibration. CH:COLUMN_TEMPERATURE 25 #ANALYSIS AN:ANALYSIS_TYPE MS #MS MS:INSTRUMENT_NAME Thermo Q Exactive Orbitrap MS:INSTRUMENT_TYPE Orbitrap MS:MS_TYPE ESI MS:ION_MODE POSITIVE MS:MS_COMMENTS the following MS parameters were used: spray voltage, 3000V; sheath gas, 18; MS:MS_COMMENTS auxiliary gas, 5; vaporizer temperature, 80 °C; ion transfer tube temperature, MS:MS_COMMENTS 300 °C; and S-lens, 30%. For nicotinic acid riboside (NAR) analysis, due to MS:MS_COMMENTS interference in the D4-NAR (M+4) channel at MS1 level, characteristic fragment MS:MS_COMMENTS ions (m/z 124.0392, 127.0581, 128.0643, and 130.0594) from MS2 spectra of NAR, MS:MS_COMMENTS D3-NAR, D4-NAR, and 13 C-NAR precursors were used for quantification. MS2 data MS:MS_COMMENTS acquisition was performed with the following parameters: isolation window, 0.8 MS:MS_COMMENTS m/z; HCD collision energy, 30%; resolution, 30,000; and a targeted mass list of MS:MS_COMMENTS m/z 256.0816, 259.1004, 260.1067, and 267.1185. To determine the concentration MS:MS_COMMENTS of 13 C-labeled NAR in the yeast extract, standards of NAR (0.16 and 0.8 ng/µL) MS:MS_COMMENTS were spiked into 5 µL 13 C yeast extract, followed by methanol extraction and MS:MS_COMMENTS LC–MS analysis. Skyline was used for MS2-based quantification. #MS_METABOLITE_DATA MS_METABOLITE_DATA:UNITS arbitrary MS_METABOLITE_DATA_START Samples 818 819 830 831 895 908 820 821 832 833 861 862 906 907 824 825 834 840 846 847 852 853 826 827 842 844 845 837 836 880 881 835 887 888 868 869 891 Std-YEmix2 Std-YEmix3 Factors Genotype:WT | Treatment:PBS | Treatment duration (hr):0 | Sample source:plasma Genotype:WT | Treatment:PBS | Treatment duration (hr):0 | Sample source:plasma Genotype:KO | Treatment:PBS | Treatment duration (hr):0 | Sample source:plasma Genotype:KO | Treatment:PBS | Treatment duration (hr):0 | Sample source:plasma Genotype:KO | Treatment:PBS | Treatment duration (hr):0 | Sample source:plasma Genotype:WT | Treatment:PBS | Treatment duration (hr):0 | Sample source:plasma Genotype:WT | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):1 | Sample source:plasma Genotype:WT | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):1 | Sample source:plasma Genotype:KO | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):1 | Sample source:plasma Genotype:KO | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):1 | Sample source:plasma Genotype:KO | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):1 | Sample source:plasma Genotype:KO | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):1 | Sample source:plasma Genotype:WT | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):1 | Sample source:plasma Genotype:WT | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):1 | Sample source:plasma Genotype:WT | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):3 | Sample source:plasma Genotype:WT | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):3 | Sample source:plasma Genotype:KO | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):3 | Sample source:plasma Genotype:KO | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):3 | Sample source:plasma Genotype:WT | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):3 | Sample source:plasma Genotype:WT | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):3 | Sample source:plasma Genotype:KO | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):3 | Sample source:plasma Genotype:KO | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):3 | Sample source:plasma Genotype:WT | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):6 | Sample source:plasma Genotype:WT | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):6 | Sample source:plasma Genotype:KO | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):6 | Sample source:plasma Genotype:WT | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):6 | Sample source:plasma Genotype:WT | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):6 | Sample source:plasma Genotype:KO | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):6 | Sample source:plasma Genotype:KO | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):6 | Sample source:plasma Genotype:KO | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):6 | Sample source:plasma Genotype:KO | Treatment:D4-NA 80 mg/kg | Treatment duration (hr):6 | Sample source:plasma Genotype:KO | Treatment:D4-NA 400 mg/kg | Treatment duration (hr):3 | Sample source:plasma Genotype:WT | Treatment:D4-NA 400 mg/kg | Treatment duration (hr):3 | Sample source:plasma Genotype:WT | Treatment:D4-NA 400 mg/kg | Treatment duration (hr):3 | Sample source:plasma Genotype:KO | Treatment:D4-NA 400 mg/kg | Treatment duration (hr):3 | Sample source:plasma Genotype:KO | Treatment:D4-NA 400 mg/kg | Treatment duration (hr):3 | Sample source:plasma Genotype:WT | Treatment:D4-NA 400 mg/kg | Treatment duration (hr):3 | Sample source:plasma Genotype:- | Treatment:NAR standard and 13C yeast | Treatment duration (hr):- | Sample source:- Genotype:- | Treatment:NAR standard and 13C yeast | Treatment duration (hr):- | Sample source:- NAR 345802 841722 73860 62718 70871 938676 464156 226053 117346 85032 103334 99740 486886 485315 837195 531612 58359 87010 722191 1347397 58970 40105 744272 930591 626865 893944 57491 73363 5891 52413 47254 399047 586476 73071 49791 307782 11386816 48021012 NAR-D3 48030 65158 50364 200091 112486 134399 611453 87761 285387 32776 215477 101025 113284 92146 NAR-D4 5757033 5860334 506378 234643 482823 306052 4832637 4340557 1626828 1630182 284 1779 1656286 2588079 207606 318339 488335 485195 609411 565196 5839621 7708172 656831 435514 6984494 NAR-13C 1044605 951680 745773 1156210 1105180 1022788 1043186 1097096 1016821 884171 807207 967659 1013301 884267 824425 801681 1022498 1083397 1037164 894530 1117073 1077702 1331172 1020349 721504 1135625 991832 1091607 949753 1122270 989935 900242 986191 996682 861993 950060 969724 697130 606145 MS_METABOLITE_DATA_END #METABOLITES METABOLITES_START metabolite_name Quantified MS2 m/z Retention Time NAR 124.0393 7.2 NAR-D3 127.0581 7.2 NAR-D4 128.0644 7.2 NAR-13C 130.0594 7.2 METABOLITES_END #END